- Bulgaria
- /
- Medical Equipment
- /
- BUL:SYN
Synthetica AD's (BUL:SYN) Weak Earnings May Only Reveal A Part Of The Whole Picture
Synthetica AD's (BUL:SYN) stock showed strength, with investors undeterred by its weak earnings report. While shareholders may be willing to overlook soft profit numbers, we believe that they should also be taking into account some other factors which may be cause for concern.
How Do Unusual Items Influence Profit?
For anyone who wants to understand Synthetica AD's profit beyond the statutory numbers, it's important to note that during the last twelve months statutory profit gained from лв6.4m worth of unusual items. While it's always nice to have higher profit, a large contribution from unusual items sometimes dampens our enthusiasm. When we analysed the vast majority of listed companies worldwide, we found that significant unusual items are often not repeated. And that's as you'd expect, given these boosts are described as 'unusual'. Synthetica AD had a rather significant contribution from unusual items relative to its profit to September 2025. As a result, we can surmise that the unusual items are making its statutory profit significantly stronger than it would otherwise be.
Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of Synthetica AD.
Our Take On Synthetica AD's Profit Performance
As we discussed above, we think the significant positive unusual item makes Synthetica AD's earnings a poor guide to its underlying profitability. For this reason, we think that Synthetica AD's statutory profits may be a bad guide to its underlying earnings power, and might give investors an overly positive impression of the company. On the bright side, the company showed enough improvement to book a profit this year, after losing money last year. Of course, we've only just scratched the surface when it comes to analysing its earnings; one could also consider margins, forecast growth, and return on investment, among other factors. If you want to do dive deeper into Synthetica AD, you'd also look into what risks it is currently facing. Every company has risks, and we've spotted 3 warning signs for Synthetica AD (of which 2 are a bit unpleasant!) you should know about.
This note has only looked at a single factor that sheds light on the nature of Synthetica AD's profit. But there are plenty of other ways to inform your opinion of a company. Some people consider a high return on equity to be a good sign of a quality business. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks with significant insider holdings to be useful.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About BUL:SYN
Synthetica AD
Through its subsidiaries, produces and sells hemodialysis and medical products in Bulgaria.
Low risk with questionable track record.
Market Insights
Community Narratives

